Physician profile
James L Schulgit
NPI 1265487201
$13,875.96
in general payments reported to CMS, 2019-2025
30 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,374 · 2020: $1,403 · 2021: $2,612 · 2022: $2,857 · 2023: $2,387 · 2024: $2,073 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,465 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,464.92 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,079.59 | 2019-2024 | Farxiga, Andexxa, Brilinta |
| Janssen Pharmaceuticals, INC | $2,380.23 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,750.24 | 2019-2024 | Jardiance |
| Amgen INC. | $1,267.19 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $919.72 | 2019-2024 | |
| Amarin Pharma, INC. | $513.41 | 2019-2022 | |
| Pfizer INC. | $443.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $436.72 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $388.50 | 2019-2024 | Camzyos |
| Kestra Medical Technology Services, INC. | $375.94 | 2022-2023 | Assure Wcd |
| Boston Scientific Corporation | $261.17 | 2019-2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $250.69 | 2020-2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $209.73 | 2019-2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $189.67 | 2019-2021 | |
| Lundbeck LLC | $185.91 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $183.90 | 2019 | |
| Novo Nordisk INC | $177.17 | 2021-2024 | Ozempic, Wegovy |
| Abbott Laboratories | $169.75 | 2025 | Mitraclip |
| Lexicon Pharmaceuticals, INC. | $169.16 | 2023-2024 | Inpefa |
| Heartflow, INC. | $124.41 | 2024 | |
| Scpharmaceuticals INC. | $70.68 | 2023-2024 | |
| Biotronik INC. | $69.63 | 2019-2022 | |
| Medtronic Vascular, INC. | $55.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $52.89 | 2019 | |
| Medtronic, INC. | $49.41 | 2021-2023 | Linq II |
| Atricure, INC. | $39.82 | 2019-2020 | |
| Cook Medical LLC | $19.51 | 2023 | Zilver Ptx |
| Actelion Pharmaceuticals US, INC. | $15.71 | 2023 | Opsumit, Uptravi |
| Medicomp INC | $15.10 | 2022 | |
| Bardy Diagnostics, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schulgit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.